Company intelligence / Profile preview

Selux Diagnostics

Boston / Charlestown, Massachusetts, United Statesseluxdx.com ↗

Ownership: Private
Employees: ~93
Development stage: Commercial

Overview

The Selux NGP System has received three FDA clearances as of early 2024. It delivers rapid antibiotic susceptibility testing results directly from positive blood cultures and isolated colonies within approximately five hours—days faster than standard methods. This enables same-day personalized antimicrobial therapy decisions to improve patient outcomes and combat antibiotic resistance. Clinical validation supported by BARDA funding has demonstrated the system’s accuracy and speed in real-world settings. The company recently raised $48 million to support US commercialization efforts.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic platform
Industry: Molecular Diagnostics

Partnerships

Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health & Human Services

Beyond the preview

Go deeper on Selux Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selux Diagnostics.

Explore the full profile